Sei Investments Co. Boosts Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL

Sei Investments Co. grew its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 4.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,198 shares of the biopharmaceutical company’s stock after purchasing an additional 1,122 shares during the quarter. Sei Investments Co.’s holdings in Madrigal Pharmaceuticals were worth $12,667,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Flagship Harbor Advisors LLC purchased a new position in shares of Madrigal Pharmaceuticals during the 4th quarter valued at about $29,000. Kemnay Advisory Services Inc. purchased a new stake in Madrigal Pharmaceuticals in the fourth quarter worth approximately $39,000. Quarry LP purchased a new stake in Madrigal Pharmaceuticals in the third quarter worth approximately $39,000. Accent Capital Management LLC grew its position in Madrigal Pharmaceuticals by 64.9% during the fourth quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 37 shares during the last quarter. Finally, Johnson Financial Group Inc. bought a new position in Madrigal Pharmaceuticals during the third quarter valued at approximately $50,000. 98.50% of the stock is currently owned by institutional investors.

Madrigal Pharmaceuticals News Summary

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra continues to drive strong revenue growth. Second-quarter revenue reached $364.25 million, up 71.2% year over year and above the $352.13 million analyst consensus, reflecting continued demand for the company’s MASH drug. Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
• Positive Sentiment: The quarterly loss was narrower than expected. Madrigal reported a loss of $1.99 per share, beating estimates ranging from $2.55 to $2.68 per share, although the loss was wider than the $1.90-per-share loss recorded a year earlier. Madrigal Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support remains favorable. Wells Fargo assigned Madrigal an Overweight rating, providing a positive signal for the company’s outlook. Madrigal Earns Overweight Rating from Wells Fargo
• Neutral Sentiment: Madrigal’s earnings call and quarterly presentation highlighted Rezdiffra’s contribution to the business and the company’s ongoing development efforts, but investors are weighing the pace of the commercial launch against the stock’s elevated valuation. Madrigal Q2 2026 Earnings Call Transcript
• Negative Sentiment: Shares fell despite the earnings beat. Investors appear concerned that Rezdiffra’s commercial growth is moderating, making the strong year-over-year revenue increase less compelling and raising expectations for evidence of sustained prescribing and sales momentum. MDGL Stock Down Despite Q2 Beat

Insider Activity at Madrigal Pharmaceuticals

In related news, Director Richard S. Levy sold 5,682 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total transaction of $2,928,730.08. Following the completion of the sale, the director directly owned 22,015 shares in the company, valued at $11,347,411.60. This represents a 20.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $495.74, for a total transaction of $516,561.08. Following the sale, the insider owned 10,033 shares of the company’s stock, valued at $4,973,759.42. This represents a 9.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,568 shares of company stock worth $3,880,711 in the last 90 days. Company insiders own 17.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on MDGL shares. Evercore set a $649.00 price target on shares of Madrigal Pharmaceuticals in a research note on Thursday, May 7th. HC Wainwright reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday. Truist Financial increased their target price on shares of Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Piper Sandler reiterated an “overweight” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Canaccord Genuity Group lifted their target price on shares of Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the stock a “buy” rating in a research report on Wednesday. Fourteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $688.20.

Madrigal Pharmaceuticals Trading Down 5.2%

Shares of MDGL stock opened at $467.32 on Friday. The business has a 50-day moving average of $516.48 and a 200 day moving average of $499.05. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.50 and a quick ratio of 3.16. Madrigal Pharmaceuticals, Inc. has a 1-year low of $290.00 and a 1-year high of $615.00. The stock has a market capitalization of $10.78 billion, a PE ratio of -36.25 and a beta of -1.05.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) EPS for the quarter, topping analysts’ consensus estimates of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative return on equity of 55.04% and a negative net margin of 25.32%.The business had revenue of $364.25 million for the quarter, compared to analysts’ expectations of $352.13 million. During the same period in the previous year, the firm earned ($1.90) EPS. The business’s quarterly revenue was up 71.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.45 earnings per share for the current year.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.